139 related articles for article (PubMed ID: 27564105)
41. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
42. The prognostic value of serum alkaline phosphatase in osteosarcoma of the limbs.
Bacci G; Dallari D; Battistini A; Orlandi M; Ferrari S; Avella M; Picci P; Casadei R; Ruggieri P
Chir Organi Mov; 1992; 77(2):171-80. PubMed ID: 1499384
[TBL] [Abstract][Full Text] [Related]
43. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
44. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
Farfalli GL; Albergo JI; Lobos PA; Smith DE; Streitenberger PD; Pallotta Rodríguez MG; Aponte-Tinao LA
Medicina (B Aires); 2015; 75(2):87-90. PubMed ID: 25919869
[TBL] [Abstract][Full Text] [Related]
45. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
46. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
47. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
[TBL] [Abstract][Full Text] [Related]
48. High levels of D-dimer correlated with disease status and poor prognosis of inoperable metastatic colorectal cancer patients treated with bevacizumab.
Zhu L; Liu B; Zhao Y; Liu L; Yang C; Yang Y; Zhong H
J Cancer Res Ther; 2014 Dec; 10 Suppl():246-51. PubMed ID: 25693928
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.
Chen J; Sun MX; Hua YQ; Cai ZD
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1205-10. PubMed ID: 24682390
[TBL] [Abstract][Full Text] [Related]
50. Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Díaz R; Salom M; Baixauli F; Gómez J; Llavador M; Castel V
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e272-7. PubMed ID: 25374283
[TBL] [Abstract][Full Text] [Related]
51. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-1908 is a biomarker for poor prognosis in human osteosarcoma.
Lian D; Wang ZZ; Liu NS
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1258-62. PubMed ID: 27097944
[TBL] [Abstract][Full Text] [Related]
53. Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study.
Ogura K; Fujiwara T; Yasunaga H; Matsui H; Jeon DG; Cho WH; Hiraga H; Ishii T; Yonemoto T; Kamoda H; Ozaki T; Kozawa E; Nishida Y; Morioka H; Hiruma T; Kakunaga S; Ueda T; Tsuda Y; Kawano H; Kawai A
Cancer; 2015 Nov; 121(21):3844-52. PubMed ID: 26194185
[TBL] [Abstract][Full Text] [Related]
54. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.
Ferrari S; Briccoli A; Mercuri M; Bertoni F; Picci P; Tienghi A; Del Prever AB; Fagioli F; Comandone A; Bacci G
J Clin Oncol; 2003 Feb; 21(4):710-5. PubMed ID: 12586810
[TBL] [Abstract][Full Text] [Related]
55. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.
Chen D; Zhang YJ; Zhu KW; Wang WC
Tumour Biol; 2013 Jun; 34(3):1895-9. PubMed ID: 23589053
[TBL] [Abstract][Full Text] [Related]
56. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
[TBL] [Abstract][Full Text] [Related]
57. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
Wang Z; Tan M; Chen G; Li Z; Lu X
IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: a Systematic Review and Meta-Analysis.
Li W; Tang Y; Song Y; Chen SH; Sisliyan N; Ni M; Zhang H; Zeng Q; Hou B; Xie X; Chang D
Cell Physiol Biochem; 2018; 45(4):1663-1676. PubMed ID: 29490291
[TBL] [Abstract][Full Text] [Related]
59. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma.
Li Z; Xiao J; Hu K; Wang G; Li M; Zhang J; Cheng G
Int J Mol Sci; 2015 Jan; 16(2):2294-306. PubMed ID: 25622249
[TBL] [Abstract][Full Text] [Related]
60. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
Shi ZW; Wang JL; Zhao N; Guan Y; He W
Cancer Biomark; 2016 Jun; 17(2):249-57. PubMed ID: 27540978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
